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Multiple system atrophy (MSA) is a rare neurodegenerative disorder with substantial knowl-
edge gaps despite recent gains in basic and clinical research. In order to make further advances,
concerted international collaboration is vital. In 2014, an international meeting involving
leaders in the ﬁeld and MSA advocacy groups was convened in Las Vegas, Nevada, to identify
critical research areas where consensus and progress was needed to improve understanding,
diagnosis, and treatment of the disease. Eight topic areas were deﬁned: pathogenesis, preclinical
modeling, target identiﬁcation, endophenotyping, clinical measures, imaging biomarkers,
nonimaging biomarkers, treatments/trial designs, and patient advocacy. For each topic area, an
expert served as a working group chair and each working group developed priority-ranked
research recommendations with associated timelines and pathways to reach the intended goals.
In this report, each groups’ recommendations are provided.
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Glossary
α-syn = α-synuclein; MSA = multiple system atrophy; SWOT = strengths, weaknesses, opportunities, and threats.
Multiple system atrophy (MSA) is a rare and devastating
neurodegenerative disorder presenting clinically with severe
autonomic failure, parkinsonism, cerebellar ataxia, and corti-
cospinal tract signs in varying combinations.1 MSA is con-
sidered an orphan disease with an annual incidence rate of
0.1–3 per 100,000 depending on age and geographic
region.2–5 The estimated prevalence rates range from 1.9 to
4.9.4,6–9 MSA is a progressive and incurable disease leading to
death typically within 9 years after symptom onset.10–17 There
are substantial knowledge gaps in the scientiﬁc understanding
of and clinical approach to MSA. The pathophysiology un-
derlying MSA is poorly understood, although abnormal forms
of α-synuclein (α-syn) appear to play a key role in the path-
ogenic neurodegenerative cascade.18 Diagnostic certainty can
be challenging and symptomatic therapies are of limited and
transient beneﬁt in alleviating disease burden.12,15 Because
MSA is a rare disease, international collaboration is critical to
generate cohorts of suﬃcient size for studying and advancing
knowledge about this disorder; such global eﬀorts can be
diﬃcult to implement.19 In 2014, an international meeting
involving leaders in the ﬁeld and MSA advocacy groups was
convened in Las Vegas, Nevada, to address these issues and
develop a roadmap for MSA-related research. A summary of
these recommendations is provided below.
Methods
Similar to the development of the 2013 NIH Alzheimer’s
Disease–Related Dementias Conference,20 the overall process
was divided into planning, preconference, conference, and
postconference activities.
Planning
Planning eﬀorts began in early 2014 when the meeting chairs
deﬁned the objectives of the meeting. The prespeciﬁed goals
of the meeting are presented in the table. The 6 objectives
were then incorporated into 7 topics, and for each topic a 5- to
6-member working group and chair were designated (see
Results). Together with the working group chairs, the meet-
ing chairs and advisory board recruited relevant researchers
for each working group.
Preconference
Each working group was tasked with developing a prioritized list
of up to 4 recommendations for their topic prior to themeeting.
Conference calls were convened for eachworking group prior to
the conference to develop draft recommendations. All recom-
mendations were based on the working group’s analysis of
current strengths, weaknesses, opportunities, and threats
(SWOT analysis) in their research area. The SWOT analysis
was summarized and incorporated into a “need” describing the
rationale for the recommendation. In addition, a “pathway” was
developed to identify the essential items to achieve the rec-
ommended goal. Thus, all recommendations had the following
predeﬁned structure: recommendation (what?), need (why?),
and pathway (how?). Complete full-text ﬁnal recommendations
from each working group are provided in appendix e-1 (links.
lww.com/WNL/A22).
Conference
The Global MSA Research Roadmap Meeting was held on No-
vember 1–2, 2014, at the Keep Memory Alive Event Center on
the campus of the Cleveland Clinic Lou Ruvo Center for Brain
Health in Las Vegas, Nevada. There were approximately 75 in-
ternational conference participants representing academia, in-
dustry, advocacy groups, and the NIH.Working groups were ﬁrst
charged to discuss and ﬁnalize their premeeting working
group recommendations during an in-person workshop at
the conference. Subsequently, each working group
presented their recommendations to the meeting participants,
which was followed by an open discussion on the proposed rec-
ommendations, their priority levels, and the anticipated timelines.
Postconference
Each working group ﬁnalized their recommendations in-
corporating conference feedback and discussion. Subsequently,
a manuscript was developed that included input from the
conference chair and co-chairs, advisory panel, and working
group chairs.
Results
The primary outcome of the conference is the prioritized
MSA research roadmap recommendation list summarized in
ﬁgures 1 and 2. Estimated timelines and pathways to reach the
intended goals were also developed and are summarized in
ﬁgures e-1 and e-2 (links.lww.com/WNL/A21). Research
recommendations are presented by topic area and prioritized
as per each working group, incorporating the meeting dis-
cussion. The complete working group documents are pro-
vided in appendix e-1 (links.lww.com/WNL/A22).
Key themes drawn from the research roadmap recom-
mendations warrant consideration. Preclinical MSA research
would beneﬁt from improved understanding of pathogenesis,
particularly the development of novel preclinical models that
more faithfully reproduceMSApathology, symptomatology, and
progression. Such models would also enable standardized pre-
clinical testing of potential therapies. Clinical research would
beneﬁt from improved diagnostic accuracy, particularly for early
diagnosis through advances in clinical and biomarker research.
Furthermore, and similar to the preclinical recommendations,
coordinated and standardized diagnostic and therapeutic
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approaches were considered essential to facilitate future collab-
oration and develop and validate outcome measures for future
clinical trials.
The Pathogenesis Working Group set 3 research priorities
with elucidation of the relationship between oligodendroglial
pathology and neuronal death viewed as the primary research
area. It was also agreed that additional work on α-syn, through
investigation of protein structure, assembly into ﬁlaments, and
propagation of abnormal structure, would signiﬁcantly ad-
vance the ﬁeld. Finally, the panel thought that additional
investigations in regional anatomic vulnerability to pathology,
initiating factors, and changes that precede α-syn accumula-
tion, aggregation, posttranslational modiﬁcations, and cell-to-
cell transmission and their role in driving disease would be
warranted. The initiation of projects providing insights into
these research priorities were estimated to require at least 3
years and formative work would not be expected to be com-
pleted before 2020.
Current in vivo MSA models incompletely replicate the dis-
ease process,21 which may contribute to their failure to predict
clinical beneﬁt from attempts at therapeutic intervention.
The Preclinical Modeling Working Group ranked the
development of novel rodent MSA models incorporating re-
cent ﬁndings from nonvertebrate models, in vitro models, as
well as human brain tissue studies as top priorities. Thus far,
behavioral studies inMSA animal models mainly have focused
on motor deﬁcits whereas nonmotor endpoints have not been
studied systematically. However, both motor and nonmotor
outcomes are pertinent for drug discovery in MSA since
patients experience motor impairment along with severe
generalized autonomic failure, cognitive deﬁcits, and other
nonmotor symptoms. Therefore, the panel identiﬁed the
characterization of existing transgenic MSA models using
nonmotor endpoints, wet biomarkers, and multimodal neu-
roimaging as another important research priority. MSA ge-
netics and underlying pathogenesis remain poorly understood
and the generation of hypothesis-blind models of MSA
(i.e., induced pluripotent stem cells) also was considered
another top research priority.
The Preclinical Target Development Working Group identi-
ﬁed α-syn as the most promising target for future interventional
therapies. It was suggested that research should focus particu-
larly on (1) measuring and reducing α-syn pathology in models
of oligodendroglial α-syn overexpression for future translation
into human trials and (2) identiﬁcation/validation of bio-
markers through bidirectional/iterative feedback with human
studies. A close collaboration between preclinical and clinical
researchers is critical to facilitate the development of reliable
biomarkers; clinical studies often generate hypotheses re-
garding which biomarkers may hold promise, and preclinical
testbeds can then be used to develop speciﬁc diagnostic tools.
After clinical validation, these newly developed tools may fa-
cilitate therapeutic development and improve patient care.
The Clinical MSA Phenotype Working Group noted that it is
essential, as with other neurodegenerative disorders, for any
eﬀective treatment to be started as early as possible in the
disease course. However, the low sensitivity of early clinical
diagnosis ofMSAmeans that the disease is typically diagnosed
at a time when the pathology is advanced.22 Therefore, the
clinical working group on MSA phenotype concluded that
developing a patient-completed clinical questionnaire and
physician-conﬁrmed checklist should improve sensitivity of
early clinical diagnosis and ranked this objective as their top
research priority. The working group recommended de-
veloping a detailed operations manual to facilitate the di-
agnosis of MSA using the current consensus criteria including
standardized wording of key clinical questions.23 As a second
step, the development of a clinical score–based aid to di-
agnose MSA without necessarily requiring sophisticated and
costly investigations would be highly warranted.
Improvements in clinical measures were also identiﬁed as
a research area that requires special attention. The Clinical
Outcome Measures Working Group agreed that the de-
velopment of a valid international rating scale based on the
revision and improvement of the existing UniﬁedMSA Rating
Scale24,25 should be the top research priority, which could be
Table Prespecified meeting objectives
1. To develop a roadmap for MSA-related research to provide a framework




• Targeting of pathologic development and spread
• Understanding divergence of α-synucleinopathy vs PD
• Disease phenotypes and outcome measures, including global registry
• Disease onset, disease progression, and therapeutic response
biomarkers
• Experimental therapeutic development
2. To identify critical needs/barriers to advance MSA research
3. To further acquaint funding agencies with MSA and unmet research/
therapeutic needs
4. To further global coalitions and collaborative efforts to advance research
in MSA
5. To engage pharmaceutical and biotechnology companies in discussions
on MSA therapeutic development
• Including MSA as a potential model disease for neurodegenerative
therapeutic development
• Including the commonality of α-synuclein in MSA and PD as integral to
disease pathology
6. To elevate awareness ofMSA throughpublicity, publication resultant from
the meeting, and engagement of stakeholders for MSA advocacy
Abbreviations: α-syn = α-synuclein; MSA = multiple system atrophy; PD =
Parkinson disease.
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achieved employing a model similar to what has recently been
conducted by the International Parkinson and Movement
Disorders Society to update the Uniﬁed Parkinson’s Disease
Rating Scale.26–28 There was consensus that an international
registry providing standardized and comprehensive pheno-
typic data linked to local biobanks/biomaterial collections
as well as imaging data would advance the ﬁeld. Thus, the
clinical outcome measure working group deﬁned the
creation of a uniﬁed dataset for MSA and implementation of an
international global registry as their second top research
priority.
The Imaging Biomarkers Working Group recognizes that pre-
vious studies provide a rich MRI repertoire with potential to be
used in diagnosis, natural history, and treatment studies.29
There is, however, lack of consistent evidence for MRI-based
changes in MSA at magnetic ﬁelds of 3.0T or higher, scarce
evidence for early MRI-based changes, and limited compara-
bility among studies given heterogeneous MRI protocols, study
populations, and diﬀerent segmentation techniques. The
working group prioritized the development of standardized
protocols for MRI-based diagnostics at current conventional
ﬁeld strengths with exploration of the sensitivity of amultimodal
approach (e.g., PET/MRI, multimodal MRI) to disease pro-
gression and preclinical diagnosis as their top priority. Another
focus area was the development and implementation of func-
tional imaging protocols with currently available tracers to
evaluate MSA-related brain networks and dopaminergic in-
tegrity using PET and SPECT. Finally, the imaging panel agreed
that development of sensitive and reproducible imaging agents
to assess molecular aspects of MSA pathology including α-syn
aggregation is warranted.
The Non-Imaging Biomarkers Working Group noted that
ﬂuid and tissue biomarker data for MSA are sparse,30 and
there is a is a critical need to standardize and validate methods
for both cross-sectional and longitudinal studies. The working
group prioritized establishing an infrastructure for standard-
ized collection of bioﬂuids (CSF and blood-based) and tissues
(standardized skin biopsy; central and autonomic nervous
system at autopsy) their top research priority. Another rec-
ommendation was the exploitation of ongoing multicenter
biomarker cohorts (both existing and future ones) in 2 ways:
(1) to determine the proﬁle of candidate, pathologic analytes
in patients with MSA through validated testing platforms; and
(2) to interrogate specimens in an unbiased manner through
complementary strategies for the discovery of potential
markers. Further research toward the development of a cuta-
neous biomarker for MSA by measuring the degree of de-
position for pathologic variants of α-syn deposition in
cutaneous autonomic nerves was also considered important.
Similar to other group recommendations, the Clinical Treat-
ments and Trials Working Group prioritized the need for de-
veloping tools to facilitate earlier diagnosis and for creating
biobanking infrastructure dedicated to MSA. In addition, pro-
spective cohort studies to characterize progression rates and
sensitivity to change over time of clinical, imaging, and other
bioﬂuid markers were ranked as top research priority. Addi-
tional recommendations were focused on the development of
Figure 1 Preclinical working groups and recommendations (priority-ranked)
α-syn = α-synuclein; iPSC = induced pluripotent stem cell; MSA = multiple system atrophy.
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novel therapies for disease modiﬁcation and promising symp-
tomatic treatments. It was recognized that advances in pre-
clinical and clinical research as outlined above are needed to
facilitate the development of novel treatments.
The Patient Advocacy Working Group highlighted the im-
portance of developing a continuing education program to
inform medical and allied health professionals about MSA,
along with establishing clinical centers of excellence, as the top
Figure 2 Clinical working groups and recommendations (priority-ranked)
ANS = autonomic nervous system; MSA = multiple system atrophy; SYN = synuclein; UMSARS = Unified MSA Rating Scale.
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priorities. In addition, a funded liaison who works with
stakeholders to access funds, cultivate the development of
innovative technologies, and nurture collaborative research
programs was considered another important goal. A public
information structure to develop and disseminate information
tailored for advocacy and awareness should be another focus
area in the next years. Finally, a collaborative network of
relevant, nonmedical organizations would be important to
strengthen advocacy and support patient-responsive research.
Discussion
In the last decade, MSA has seen an encouraging increased
interest among clinical and experimental scientists, along with
improved international collaboration. In this spirit, a dedi-
cated MSA research roadmap meeting that involved global
leading MSA researchers was undertaken, with the over-
arching goal of helping to further coordinate thinking and
eﬀorts to enable progress toward clinically meaningful ther-
apeutics. This report reﬂects the carefully considered rec-
ommendations developed collaboratively by a large group of
leaders in the ﬁeld and is intended to be an authoritative (but
not the only) source for guiding future research eﬀorts and
priorities regarding MSA.
Each of the recommendations in this report provides im-
portant research goals on its own. During the conference,
diﬀering opinions about the current state and future direc-
tions were discussed and, upon agreement, incorporated into
the ﬁnal recommendation. Hence, the prioritized recom-
mendations list reﬂects a thoughtful, collaborative, and eﬃ-
cient approach to ultimately prevent, stop, or cure MSA. It is
important to mention that lower-ranked recommendations in
this report do not reﬂect a lack of importance; inclusion
suggests that the research objective is indeed among the top
priority items in the ﬁeld. In addition, these recommendations
are not meant to be exclusive. It will be critical to continuously
explore new research areas as they emerge, and modify the
research roadmap accordingly. In addition, we recognize
achievement of these research goals is ambitious and will
require not only funding but also the continued commitment
of established as well as new investigators in the MSA ﬁeld.
The present recommendations constitute an initial frame-
work for future research eﬀorts in MSA. These goals may be
reﬁned in the future, and it is recognized that an overall
ranking irrespective of the diﬀerent areas of research may be
useful to the research community and cost-eﬀectiveness is also
an important consideration.
Although major knowledge gaps remain, the prerequisites for
change are in place: (1) a passionate and committed research
community to execute this research plan, (2) a growing in-
ternational collaborative that encompasses preclinical work as
well as clinical research, and (3) a fully dedicated and well-
organized network of advocacy. The rate of progress is limited
in part by the rarity of the illness and the available resources,
highlighting the vital role of MSA advocacy and collaboration.
Our sincere hope is that the Global MSA Research Roadmap
recommendations will help to advance research in MSA,
broaden the knowledge and awareness of MSA, recruit tal-
ented scientists from neighboring disciplines, further raise
awareness, and thus allow us as a community to develop ef-
fective therapies as quickly as possible for this fatal disease.
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